Literature DB >> 24068381

Therapeutic pulmonary artery stenting for metastatic bronchial carcinoid.

Daniel B F Vawdrey1, Samantha Fitzsimmons, Gruschen R Veldtman, John-Paul Carpenter.   

Abstract

We present a case of a middle-aged man with a 3-month history of progressive shortness of breath and peripheral oedema. Ten years prior to this, he had undergone a left pneumonectomy for metastatic bronchial carcinoid. Clinical examination revealed significant right heart failure, supported by transthoracic echocardiography. CT pulmonary angiogram revealed the cause to be marked progression of the bronchial carcinoid causing severe external compression of right pulmonary artery (RPA). In view of the distressing symptoms, a palliative endovascular intervention to the RPA was attempted to relieve obstruction, improve blood flow through the right lung and offload the right ventricle. This was performed under general anaesthesia involving interventional cardiology and radiology specialists together with a specialist anaesthetic team with extensive experience of managing carcinoid patients. The result was a marked improvement in symptoms and right heart function and the patient was discharged 2 days later.

Entities:  

Mesh:

Year:  2013        PMID: 24068381      PMCID: PMC3794312          DOI: 10.1136/bcr-2013-201123

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

1.  Metastatic carcinoid tumour mimicking cholecystitis, and a rare case of intussusception.

Authors:  L R Poynter; N Tewari; H T Khawaja
Journal:  BMJ Case Rep       Date:  2011-03-08

2.  Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients.

Authors:  P F Quaedvlieg; O Visser; C B Lamers; M L Janssen-Heijen; B G Taal
Journal:  Ann Oncol       Date:  2001-09       Impact factor: 32.976

3.  Prognosis of carcinoid heart disease: analysis of 200 cases over two decades.

Authors:  Jacob E Møller; Patricia A Pellikka; Alain M Bernheim; Hartzell V Schaff; Joseph Rubin; Heidi M Connolly
Journal:  Circulation       Date:  2005-11-14       Impact factor: 29.690

4.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

Authors:  Anja Rinke; Hans-Helge Müller; Carmen Schade-Brittinger; Klaus-Jochen Klose; Peter Barth; Matthias Wied; Christina Mayer; Behnaz Aminossadati; Ulrich-Frank Pape; Michael Bläker; Jan Harder; Christian Arnold; Thomas Gress; Rudolf Arnold
Journal:  J Clin Oncol       Date:  2009-08-24       Impact factor: 44.544

Review 5.  Bronchopulmonary neuroendocrine tumors.

Authors:  Bjorn I Gustafsson; Mark Kidd; Anthony Chan; Max V Malfertheiner; Irvin M Modlin
Journal:  Cancer       Date:  2008-07-01       Impact factor: 6.860

Review 6.  Carcinoid syndrome.

Authors:  J Bendelow; E Apps; L E Jones; G J Poston
Journal:  Eur J Surg Oncol       Date:  2007-12-18       Impact factor: 4.424

7.  A 5-decade analysis of 13,715 carcinoid tumors.

Authors:  Irvin M Modlin; Kevin D Lye; Mark Kidd
Journal:  Cancer       Date:  2003-02-15       Impact factor: 6.860

8.  Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned.

Authors:  Mark Bloomston; Osama Al-Saif; Dori Klemanski; Joseph J Pinzone; Edward W Martin; Bryan Palmer; Gregory Guy; Hooman Khabiri; E Christopher Ellison; Manisha H Shah
Journal:  J Gastrointest Surg       Date:  2007-03       Impact factor: 3.267

9.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs).

Authors:  John K Ramage; A Ahmed; J Ardill; N Bax; D J Breen; M E Caplin; P Corrie; J Davar; A H Davies; V Lewington; T Meyer; J Newell-Price; G Poston; N Reed; A Rockall; W Steward; R V Thakker; C Toubanakis; J Valle; C Verbeke; A B Grossman
Journal:  Gut       Date:  2011-11-03       Impact factor: 23.059

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.